AKBA Stock Analysis: Buy, Sell, or Hold?
AKBA - Akebia Therapeutics, Inc.
$1.31
-0.01 (-0.76%)
▼
5d:
+2.34%
30d:
+5.65%
90d:
-6.43%
BUY
HIGH Confidence
Analysis Updated: Aug 3, 2026 12:00 AM ET
Earnings: Aug 05, 2026
TODAY
Get Alerted When AKBA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: AKBA shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: AKBA shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: AKBA is currently trading at $1.31, which is considered fair relative to its 30-day fair value range of $1.19 to $1.39. From a valuation perspective, the stock is trading at a discount (Forward PE: -6.9) compared to its historical average (12.4). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, AKBA is in a downtrend. Immediate support is located at $1.19, while resistance sits at $1.36.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $4.20 (+220.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, AKBA is in a downtrend. Immediate support is located at $1.19, while resistance sits at $1.36.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $4.20 (+220.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.19 -
$1.39
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.1%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 220.6% below Wall St target ($4.20)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$1.19 -
$1.39
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.19
Resistance Level
$1.36
Current Trend
Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.89
Wall Street Target
$4.20
(+220.6%)
Revenue Growth (YoY)
-6.6%
Profit Margin
-8.8%
PE vs Historical
-6.9 vs 12.4
CHEAP
Share & Embed Analysis
Last updated: August 04, 2026 9:33 AM ET
Data refreshes hourly during market hours. Next update: 10:33 AM
Data refreshes hourly during market hours. Next update: 10:33 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AKBA showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
John P Butler
BUY
69270 shares
2026-03-04
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$211 | 58 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$112 | 49 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 59 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$113 | 46 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$663 | 48 HOLD |
Advanced AKBA Option Strategies
Professional options setups generated by AI based on today's AKBA price and gamma walls.
